Liothyronine (T3): a short half-life, a suppressed TSH, and a real argument

T4 is a prohormone; T3 is the hormone. Taking it directly skips the conversion step, and it also skips most of the buffering that makes thyroid replacement forgiving. Two consequences follow, and both are about measurement.

Skipping the conversion step

Established clinical use Triiodothyronine binds the thyroid hormone receptor directly. Every effect attributed to thyroid hormone — metabolic rate, cardiac output, thermogenesis, cognition — is a T3 effect, and T4 produces them only after deiodinase enzymes remove an iodine. Taking T3 removes that step, which is the entire argument for it: someone whose conversion is impaired gets the hormone anyway.

It also removes the buffer. The body normally holds a large, slowly turning pool of T4 and converts from it as needed, which smooths supply. Dosing T3 directly replaces a regulated conversion with a fixed schedule, and the app models its half-life at about a day against thyroxine’s week. That is why it is described in split doses, and why the level over a day is a series of peaks rather than a plateau.

Two measurement problems it creates

The first is TSH. Established clinical use Therapeutic T3 suppresses thyroid-stimulating hormone, and that is expected rather than a finding. But it means the marker that titrates T4 therapy stops working here: a suppressed TSH on T3 tells you the pituitary is seeing hormone, not whether the dose is right. Whatever the target is, TSH is not it.

The second is the free T3 measurement itself. With a day-long half-life and split dosing, a level drawn two hours after a dose is a peak and a level drawn before the next one is a trough, and they can differ substantially. A free T3 without a recorded interval since the last dose is close to uninterpretable, and comparing two of them drawn at different points is worse than having neither. The thyroid panel page covers what the individual values mean.

Those two together are why this is a harder drug to run than levothyroxine, not a stronger one. The feedback loop that makes T4 forgiving has been removed at both ends.

What the evidence says, and the risk that accrues quietly

Off-label or community practice The clinical argument is about people who remain symptomatic on levothyroxine with a normal TSH. Combination T4 and T3 therapy is the usual proposal, and the randomised trials have mostly not found consistent benefit over T4 alone on the outcomes they measured — while some preference studies have found patients choosing combination therapy when blinded. Those two findings are not contradictory and neither settles it. Anyone telling you the question is closed in either direction is overstating.

Established clinical use The risk side is better established. Sustained excess thyroid hormone reduces bone mineral density and raises the incidence of atrial fibrillation, and both accumulate silently over years rather than announcing themselves. This is the reason T3 is described as physician-supervised everywhere in the app’s own entry, and the reason resting heart rate and bone density appear on the monitoring panel alongside the hormones.

Symptoms of too much overlap with the symptoms people started treatment for — palpitations, anxiety, poor sleep, heat intolerance — which makes self-titration particularly unreliable here. Anything on that list belongs with the clinician who prescribed, read against your own lab’s printed intervals.

How long one dose lasts

Try other intervals on the half-life and steady-state calculator, which runs the same function against whatever cadence you type.

The dosing rows the app records

Established clinical use Reproduced from the app’s reference so you can see what it holds, not as a recommendation. Which row applies to a particular person, if any, is a clinical decision this page does not make — and rows describing supraphysiological or post-cycle use are filtered out before this table is built, so what you see here is a subset.

What the app monitors alongside it

The panel below is the app’s own monitoring note for Liothyronine (T3), verbatim. The analytes in it that have a page here are linked; those pages cover what each one measures, which assay produced it and how to read a trend.

• Free versus total testosterone, and the three ways labs get the free number
• Thyroid panel

Drawbacks and risks the app records

From the app’s own entry. The bone and cardiac items are the ones that do not produce a symptom until they are advanced, which is what makes them the ones to plan around.

• Short half-life — requires multiple daily doses or sustained-release
• Risk of hyperthyroidism (palpitations, anxiety, insomnia) if overdosed
• Bone density loss with long-term excess dosing
• Cardiac risk at supraphysiological doses
• Requires careful titration and monitoring
• Suppresses endogenous thyroid production

Interaction rules that name Liothyronine (T3)

From the app’s interaction data, filtered so no rule naming a compound this site does not publish appears. Not exhaustive, and not a safety clearance: a combination that is not listed is one nobody has documented here, which is not the same as one that is fine. The combination checker has the rest.

Questions people actually ask

Why is my TSH suppressed on T3?

Because exogenous T3 feeds back on the pituitary directly. It is expected on therapeutic doses rather than a new finding, and it is why TSH cannot be used to titrate here the way it is with levothyroxine.

When should free T3 be drawn?

At a consistent point relative to the dose, recorded with the result. With a day-long half-life and split dosing the value moves substantially across the day, so the interval is part of the measurement rather than a detail beside it.

Is combination T4 and T3 better than T4 alone?

The randomised trials have mostly not shown consistent benefit on measured outcomes; some blinded preference studies have found patients favouring combination therapy. The question is open, and it is a prescribing conversation rather than one a page can answer.

What does "sustained-release T3" change?

The intent is to flatten the peaks a short half-life produces. Compounded slow-release preparations vary in how well they achieve that, and a preparation whose release profile is not characterised does not remove the measurement problem — it hides it.

Where the load-bearing numbers come from

Named rather than linked. Publisher URLs move, and a citation that resolves to a 404 two years from now is worse than one you can search for by name — every entry below is findable from the title and year alone.